Merck & Co., Inc. $MRK Position Raised by Avaii Wealth Management LLC

Avaii Wealth Management LLC boosted its position in Merck & Co., Inc. (NYSE:MRK) by 79.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,280 shares of the company’s stock after purchasing an additional 6,775 shares during the period. Merck & Co., Inc. makes up about 0.6% of Avaii Wealth Management LLC’s portfolio, making the stock its 25th largest holding. Avaii Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $1,608,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC boosted its stake in Merck & Co., Inc. by 237.4% during the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after buying an additional 216 shares in the last quarter. Kilter Group LLC acquired a new position in Merck & Co., Inc. during the second quarter worth about $27,000. Bare Financial Services Inc raised its position in Merck & Co., Inc. by 51.9% in the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock worth $29,000 after acquiring an additional 125 shares in the last quarter. Barnes Dennig Private Wealth Management LLC raised its position in Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after acquiring an additional 266 shares in the last quarter. Finally, Evolution Wealth Management Inc. acquired a new stake in Merck & Co., Inc. in the 2nd quarter valued at about $31,000. 76.07% of the stock is owned by institutional investors.

Insider Activity

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 121,573 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the sale, the executive vice president directly owned 68,916 shares of the company’s stock, valued at $8,211,341.40. The trade was a 63.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Chirfi Guindo sold 20,000 shares of the stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the sale, the chief marketing officer owned 80,615 shares of the company’s stock, valued at $9,825,356.20. The trade was a 19.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on MRK shares. UBS Group raised their price objective on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Guggenheim increased their target price on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a report on Monday, December 29th. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $82.00 to $130.00 in a research report on Thursday, December 18th. Finally, Scotiabank upped their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “sector outperform” rating in a report on Thursday, December 4th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $127.13.

Merck & Co., Inc. Price Performance

NYSE MRK opened at $118.90 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The company has a market cap of $293.97 billion, a PE ratio of 16.33, a PEG ratio of 2.31 and a beta of 0.27. The stock’s 50-day moving average price is $116.43 and its two-hundred day moving average price is $101.56.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the company posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 46.70%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck agreed to acquire Terns Pharmaceuticals for about $6.7 billion to add TERN‑701, an investigational CML drug that could meaningfully strengthen Merck’s hematology/oncology lineup ahead of Keytruda’s patent cliff. Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
• Positive Sentiment: Citi raised its price target on MRK to $125 (from $120), reflecting continued analyst recognition of Merck’s profitability and strategic M&A. Citi Raises its Price Target on Merck & Co. (MRK) to $125 from $120
• Positive Sentiment: Agilent received FDA approval for the PD‑L1 IHC 22C3 pharmDx as a companion diagnostic for Keytruda in esophageal/GEJ carcinoma—supportive for continued clinical use of Keytruda where indicated. This can help sustain Keytruda demand in approved indications near-term. Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx
• Neutral Sentiment: Heightened investor interest and searches on Merck point to increased attention and volume as the market digests the deal and guidance; this can amplify intraday moves but is not directional on fundamentals. Investors Heavily Search Merck & Co., Inc. (MRK)
• Neutral Sentiment: Merck held an M&A investor call and provided materials/transcript — useful for detail but mainly confirms terms and rationale rather than changing the deal. Merck & Co., Inc. (MRK) M&A Call Transcript
• Negative Sentiment: Analysts and media note potential rival interest in Terns; William Blair and others suggest the $53/shr offer may undervalue Terns’ upside, implying Merck could face a bidding contest or need to increase the price. That raises transaction risk and potential dilution/cost. Merck’s $6.7 billion Terns acquisition may face rival interest: Analyst
• Negative Sentiment: An investor‑rights law firm is investigating whether Terns shareholders are getting fair value, which can delay closing or lead to litigation/negotiation that complicates the deal timeline and integration. Terns Pharmaceuticals Investor Alert

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.